Stay updated with breaking news from லாரி மிம்ம்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Participants included existing major shareholders (Nestlé Heath Science, Biosynex SA) management and new investors. The company intends to use the funds to move forward with FDA submissions for the platform and to expand the test menu for gastroenterologists. Led by CEO and CSO Dr. Larry Mimms and President and CFO Peter Westlake, ProciseDx provides a broad portfolio of rapid diagnostic tests for the physician’s office, which use a finger prick blood sample or a stool sample and have a turn-around time of 2-5 minutes. ProciseDx has obtained CE Mark on its instrument and on four gastroenterology (GI) assays which were launched in Q3 2020. The company has established distribution relationships in more than 15 countries in Europe, Middle East and Africa (EMEA) and expects to continue its market expansion for the rest of 2021. Already over 100 instruments have been shipped to EMEA and further growth is expected in the second half of 2021. The company expects revenues ....
ProciseDx Announces $13 Million Convertible Note Financing and Strong International Growth prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.